Prostate-Specific Antigen Screening: Time to Change the Dominant Forces on the Pendulum.

Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection. Int J Mol Sci (2017) 0.75

Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05

Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet (2014) 11.01

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48

Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. JAMA (2015) 5.10

Accuracy of self-reported cancer-screening histories: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2008) 4.62

Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2007) 3.24

Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med (2016) 3.02

Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69

Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA (2014) 2.42

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38

Reevaluating PSA Testing Rates in the PLCO Trial. N Engl J Med (2016) 2.29

Screening for prostate cancer. Cochrane Database Syst Rev (2013) 2.29

Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw (2016) 2.05

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. Urology (2016) 2.05

Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Eur Urol (2013) 1.69

Prostate Cancer Screening. Am Fam Physician (2015) 1.42

The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control (2012) 1.36

Recruitment strategies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: the first six years. Control Clin Trials (2000) 1.25

Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer (2003) 1.18

Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw (2015) 0.98

National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol (2014) 0.95

Trends in prostate-specific antigen test use, 2000-2005. Public Health Rep (2011) 0.94

Correlates of prostate-specific antigen testing in a large multiethnic cohort. Am J Manag Care (2009) 0.84

The Pendulum of Prostate Cancer Screening. JAMA (2015) 0.82

Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2006) 0.78